Effects enalapril neuroendocrine activation prognosis severe congestive heart failure follow-up CONSENSUS trial CONSENSUS Trial Study Group study patients severe heart failure New York Heart Association functional class IV centers Scandinavia treatment placebo enalapril addition usual treatment heart failure initial titration period daily doses enalapril end trial placebo-treated patients enalapril-treated patients alive survival figures months completion trial follow-up placebo group significant positive association mortality baseline levels norepinephrine epinephrine angiotensin II aldosterone atrial natriuretic peptide association enalapril-treated patients results effects enalapril mortality counteraction neuroendocrine activation general renin-angiotensin system particular 